REGENXBIO Inc. (RGNX)

REGENXBIO is a clinical-stage gene therapy company whose 405.7% YoY revenue surge — likely driven by a major licensing or royalty milestone — has reignited analyst interest, with 9 of 11 covering analysts rating the stock a Buy and a consensus price target of $24.55 implying over 120% upside. The company's AAV gene therapy pipeline, including candidates in rare diseases and ophthalmology, represents a significant long-term value driver if clinical catalysts convert. The primary risk is sustained cash burn with no near-term profitability, leaving the stock highly dependent on pipeline execution and external funding or partnership milestones.

• Pipeline readout: Near-term clinical data from lead gene therapy programs (e.g., rare disease or ophthalmology indications) could serve as major re-rating events for the stock.
• Licensing and royalty revenue: Any additional out-licensing deals or royalty-generating agreements similar to those driving the 405.7% revenue spike could meaningfully extend the company's cash runway.
• Potential partnership or M&A activity: Strong analyst conviction and a depressed share price relative to pipeline value make RGNX a credible acquisition target for larger biopharma players seeking gene therapy assets.

• Ongoing cash burn: With negative earnings and a forward P/E of -4.8x, the company faces significant cash consumption risk; any need to raise equity capital could dilute shareholders substantially at current price levels.
• Clinical trial failure: Gene therapy programs carry high binary risk — a single pivotal trial miss could erase a large portion of the stock's pipeline-attributed value.
• Revenue concentration risk: The 405.7% revenue growth appears milestone-driven rather than recurring; a reversion to lower baseline revenues could disappoint investors and pressure the stock sharply.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →